UroGen Pharma Ltd.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a URGN research report →
Companywww.urogen.com
UroGen Pharma Ltd. , a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.
- CEO
- Elizabeth A. Barrett
- IPO
- 2017
- Employees
- 234
- HQ
- Princeton, NJ, US
Price Chart
Valuation
- Market Cap
- $1.47B
- P/E
- -11.38
- P/S
- 10.48
- P/B
- -12.21
- EV/EBITDA
- -13.39
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 89.85%
- Op Margin
- -77.02%
- Net Margin
- -94.83%
- ROE
- 121.52%
- ROIC
- -50.85%
Growth & Income
- Revenue
- $109.79M · 21.45%
- Net Income
- $-153,494,000 · -20.98%
- EPS
- $-3.19 · -7.77%
- Op Income
- $-124,863,000
- FCF YoY
- -67.66%
Performance & Tape
- 52W High
- $32.37
- 52W Low
- $3.42
- 50D MA
- $22.25
- 200D MA
- $21.08
- Beta
- 1.59
- Avg Volume
- 959.80K
Get TickerSpark's AI analysis on URGN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 8, 26 | Schoenberg Mark | sell | 10,000 |
| Feb 26, 25 | Robinson James A. Jr. | other | 2,000 |
| Feb 26, 25 | Robinson James A. Jr. | other | 2,000 |
| Jan 31, 26 | Barrett Elizabeth A. | other | 153,195 |
| Jan 31, 26 | Smith Jason Drew | other | 3,333 |
| Feb 3, 26 | Smith Jason Drew | sell | 3,217 |
| Jan 31, 26 | Smith Jason Drew | other | 5,500 |
| Feb 3, 26 | Smith Jason Drew | sell | 2,654 |
| Feb 3, 26 | Smith Jason Drew | sell | 1,608 |
| Jan 31, 26 | Smith Jason Drew | other | 6,667 |
Our URGN Coverage
We haven't published any research on URGN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate URGN Report →